A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial)

Background: Platinum-containing regimens are widely used as first-line chemotherapy for unresectable pancreatic neuroendocrine carcinoma (NEC), but second-line chemotherapies have yet to be established. Objectives: We evaluated the safety and efficacy of everolimus in patients with pancreatic NEC refractory or intolerant to platinum-containing chemotherapy. Methods: This study was a prospective, multicenter, phase II trial in patients with pancreatic NEC after platinum-containing chemotherapy. Everolimus treatment was continued until disease progression or intolerable toxicity was observed. The primary endpoint was progression-free survival (PFS). Results: Participants comprised 25 patients. Median age was 63 years, median PFS was 1.2 months (95% confidence interval [CI] 0.9–3.1 months), median overall survival was 7.5 months (95% CI 3.1–13.5 months), overall response rate was 0%, and disease control rate was 39.1%. Common grade 3/4 adverse events were hyperglycemia (20%), thrombocytopenia (16%), and anemia (16%). Conclusion: The efficacy of everolimus was limited in patients with unresectable pancreatic NEC.

[1]  E. Raymond,et al.  Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms , 2018, Neuroendocrinology.

[2]  H. Sorbye,et al.  ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas , 2016, Neuroendocrinology.

[3]  U. Knigge,et al.  Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas , 2014, Journal of Cancer.

[4]  J. Galván,et al.  Prolonged Clinical Benefit of Everolimus Therapy in the Management of High-Grade Pancreatic Neuroendocrine Carcinoma , 2013, Case Reports in Oncology.

[5]  F. Rea,et al.  mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. , 2013, Endocrine-related cancer.

[6]  A. Kjaer,et al.  Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas , 2012, TheScientificWorldJournal.

[7]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .

[8]  S. Knappskog,et al.  Clinical effect of temozolomide‐based chemotherapy in poorly differentiated endocrine carcinoma after progression on first‐line chemotherapy , 2011, Cancer.

[9]  D. Coppola,et al.  Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Milione,et al.  Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges , 2011, Targeted Oncology.

[11]  M. Miyazaki,et al.  Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors , 2010, Cancer Chemotherapy and Pharmacology.

[12]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[13]  Elizabeth H. Wood,et al.  The National Comprehensive Cancer Network (NCCN). , 2004 .

[14]  M. Fjällskog,et al.  Treatment with cisplatin and etoposide in patients with neuroendocrine tumors , 2001, Cancer.

[15]  M. Ducreux,et al.  Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin , 1999, British Journal of Cancer.

[16]  L. Kvols,et al.  Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms , 1991, Cancer.